当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Oliver Lorman
The blood-brain barrier is a vital protective barrier that shields the central nervous system from potentially harmful substances circulating in the bloodstream. At the heart of its functionality lie drug transporters-specialized proteins embedded in BBB endothelial cells that regulate the passage of molecules between the bloodstream and the brain. This article explores the intricate role of drug transporters within the BBB, presenting their dual nature as both protective agents and challenges in drug delivery. Efflux and influx transporters shape the brain’s exposure to therapeutic agents, posing both opportunities and obstacles. Efflux transporters safeguard the brain by actively pumping out xenobiotics, yet their presence limits drug efficacy by reducing brain penetration. Influx transporters, facilitating nutrient and neurotransmitter transport, offer potential for enhanced drug delivery. This review discusses strategies to overcome transporter-mediated barriers, including transporter inhibitors, prodrug designs, and innovative nanotechnological approaches. Achieving a delicate balance between harnessing the protective properties of drug transporters and circumventing their restrictive impact is essential for advancing targeted therapies for neurological disorders.